
Is REGN (Regeneron Pharmaceuticals, Inc.) Halal or Haram?
Regeneron Pharmaceuticals successfully passes all AAOIFI Shariah screens, making it a Halal investment. The company's debt-to-market cap ratio is exceptionally low at 3.6%, and its cash-to-market cap sits comfortably at 11.3%. However, investors should note that interest income to revenue is exactly on the borderline at 5.00%, requiring close monitoring in future quarters.
Price Chart (5D)
REGN — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-05-01 | 703.02 | 714.48 | 700.26 | 701.42 | 729K | -0.23% |
| 2026-04-30 | 693.08 | 708.44 | 688.95 | 707.06 | 1.1M | +2.02% |
| 2026-04-29 | 705.11 | 708.80 | 668.85 | 686.36 | 1.8M | -2.66% |
| 2026-04-28 | 751.37 | 754.00 | 730.90 | 731.77 | 569K | -2.61% |
| 2026-04-27 | 745.47 | 756.40 | 743.61 | 744.44 | 603K | -0.14% |
| 2026-04-24 | 760.00 | 761.96 | 736.71 | 751.57 | 810K | -1.11% |
| 2026-04-23 | 750.99 | 767.21 | 747.26 | 766.02 | 929K | +2.00% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for REGN
Business Activity
Permissible
Regeneron's business activity passes Shariah screening as its core operations involve developing and manufacturing permissible life-saving medicines, such as EYLEA for eye diseases and Dupixent for asthma.
Debt / Market Cap
3.56%
Interest Income
5.00%
Cash & Securities
11.32%
About Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that discovers and commercializes medicines for serious medical conditions. Its flagship products include EYLEA, an injection used to treat retinal diseases like macular degeneration, and Dupixent, a widely used treatment for atopic dermatitis and asthma.
For Muslim investors, Regeneron represents a Halal investment opportunity within the healthcare sector, having successfully passed all four AAOIFI screening criteria. The company's core business of developing therapeutic medicines is fundamentally permissible, aligning well with Islamic principles of preserving life and health.
From an Islamic finance perspective, Regeneron boasts an incredibly strong balance sheet with a debt-to-market cap ratio of just 3.6%, well below the 33% threshold. Its cash and interest-bearing securities also pass comfortably at 11.3% of its market capitalization, indicating minimal reliance on conventional, interest-based leverage.
While the stock is currently compliant, halal investors must pay strict attention to Regeneron's interest income, which currently sits exactly at the 5.00% AAOIFI maximum limit. Any slight increase in interest-generating cash equivalents could push the stock into non-compliant territory in upcoming earnings reports, making routine dividend purification and quarterly monitoring essential.
CEO
Leonard S. Schleifer
Employees
15,158
IPO Date
1991-04-02
Headquarters
Tarrytown, NY, US
Website
www.regeneron.comREGN Key Financial Statistics
Revenue
$14.34B
Net Income
$4.50B
EPS (Diluted)
$41.48
Stock Price
731.77
Beta
0.40
52-Week Range
476.49-821.11
Total Debt
$2.71B
Total Equity
$31.26B
Current Ratio
4.13
REGN Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
+1.0%
Prior year: $14.20B
Net Cash
$412.2M
Cash: $3.12B — Debt: $2.71B
R&D Spending
$5.85B
% of Revenue
40.8%
Frequently Asked Questions About REGN
Is REGN (Regeneron Pharmaceuticals, Inc.) stock halal to invest in?▾
What does Regeneron Pharmaceuticals, Inc. do?▾
What screening criteria were used for REGN?▾
Does REGN require income purification?▾
When was REGN last screened?▾
Disclaimer
This shariah compliance assessment for REGN (Regeneron Pharmaceuticals, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.